Abstract:BACKGROUND & AIMS: There is no satisfactory way to identify patients who will maintain a response after discontinuation of nuleos(t)ide analogue therapy for chronic hepatitis B virus (HBV) infection. We investigated whether patients with negative results from tests for HBV DNA and HBV RNA (double negative) at the end of treatment maintain a long-term response to treatment. METHODS: We performed a post-hoc analysis of data from a 2-year multi-center randomized controlled trial, and its long-term extension trials, on 130 patients with chronic HBV infection who were positive for the HB e antigen (HBeAg-positive; mean age, 30.8 +/- 6.9 years; 72.3% male) and received telbivudine with or without adefovir and stopped therapy after they had HBeAg seroconversion and levels of HBV DNA <300 copies/mL for at least 48 weeks (evaluation cohort). Clinical and laboratory assessments were made every 12 or 16 weeks until clinical relapse (defined as HBV DNA > 2000 IU/mL and level of alanine aminotransferase more than 2-fold the upper limit of normal) or until 4 years off treatment. We validated our findings in a cohort of 40 HBeAg-positive patients (36.5 +/- 9.4 years old; 72.5% male) treated with entecavir or tenofovir, and followed after discontinuation for up to 5.5 years. Patients were considered to be negative for HBV DNA if it was not detected in the COBAS Taqman assay. Patients were considered to be negative for HBV RNA if it was not detected by quantitative real-time PCR with 2 different pairs of primers. RESULTS: After 4 years off treatment, in the evaluation cohort, 30.8% of patients had a clinical relapse, 54.7% had virologic relapse (HBV DNA >2000 IU/mL in 2 tests), and 16.8% had reappearance of HBeAg in 2 tests (reversion). A significantly lower proportion of double negative patients had a clinical relapse 4 years later (2/35; 8.0%) than of patients who tested positive for either HBV DNA or RNA (32/102; 31.4%; P = .018). In the validation cohort, after 5.5 years of follow up, a lower proportion of double negative patients had clinical relapse (2/13; 15.4%) than of patients who tested positive for either HBV DNA or RNA at the end of treatment (9/27; 33.3%; P = .286) CONCLUSIONS: In an analysis of data from 2 independent cohorts, we associated negative results from tests for HBV DNA and RNA (double negative) at the end of treatment with continued response 4 or more years after discontinuation of therapy in HBeAg-positive patients. These results might be used to identify the best candidates for discontinuation of nuleos(t)ide analogue therapy.

Predictive Value of HBsAg for Off-treatment Response in HBeAg-negative Chronic Hepatitis B Patients.

HBcrAg, Pg RNA and HBsAg Dynamically Supervise the Seroconversion of HBsAg with Anti-Viral Therapy "loss of HBsAg" Maybe Not a Good End-Point of Anti-Viral Therapy

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse after Discontinuation of Nucleos(t)ide Analogue Therapy in Patients with Chronic Hepatitis B: A Prospective Stop Study

Association Between Negative Results from Tests for HBV DNA and RNA and Durability of Response after Discontinuation of Nucles(t)ide Analogue Therapy.

Lower End of Treatment HBsAg and HBcrAg Were Associated with HBsAg Loss after Nucleos(t)ide Analog Cessation

Limited Value of HBV‐RNA for Relapse Prediction After Nucleos(t)ide Analogue Withdrawal in HBeAg‐negative Hepatitis B Patients

HBsAg ≤ 135 IU/mL or HBcrAg ≤ 3.6 logU/mL was associated with HBsAg loss after nucleos(t)ide analogue cessation

HBeAg-positive Patients with HBsAg < 100 IU/mL and Negative HBV RNA Have Lower Risk of Virological Relapse after Nucleos(t)ide Analogues Cessation.

Predictors of Nucleos(t)ide Analogues Discontinuation Relapse: Hepatitis B Virus RNA versus Hepatitis B Surface Antigen

On-treatment Quantitative Hepatitis B E Antigen Predicted Response to Nucleos(t)ide Analogues in Chronic Hepatitis B

On-treatment Serum HBsAg Level is Predictive of Sustained Off-Treatment Virologic Response to Telbivudine in HBeAg-positive Chronic Hepatitis B Patients

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy

Predictors of Relapse after Cessation of Nucleos(t)ide Analog Treatment in HBeAg-negative Chronic Hepatitis B Patients: A Meta-Analysis

Hepatitis B Core-Related Antigen is a Biomarker for Off-Treatment Relapse after Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B

Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B

Predictive Value of Th17 and Treg Cells at Baseline for HBsAg Loss in Chronic Hepatitis B Patients with Low HBsAg Quantification Treated with Pegylated Interferon and Nucleos(t)ide Analogue

Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B.

Predictive Value of Serum ALT and T-cell Receptor Beta Variable Chain for HBeAg Seroconversion in Chronic Hepatitis B Patients During Tenofovir Treatment

HBV DNA and HBsAg: Early Prediction of Response to Peginterferon Α-2A in HBeAg-Negative Chronic Hepatitis B.